BIOGEN INC. Debt Instrument, Fair Value Disclosure
BIOGEN INC. (BIIB) had Debt Instrument, Fair Value Disclosure of $5.20 billion as of 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2023-11-08
- 2023-09-30: Debt Instrument, Fair Value Disclosure $5.20B.
- 2023-06-30: Debt Instrument, Fair Value Disclosure $5.53B.
- 2023-03-31: Debt Instrument, Fair Value Disclosure $5.64B.
- 2022-12-31: Debt Instrument, Fair Value Disclosure $5.41B.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2023-09-30 | $5.20B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $5.53B 10-Q · filed 2023-07-25 |
| 2023-03-31 | $5.64B 10-Q · filed 2023-04-25 |
| 2022-12-31 | $5.41B 10-Q · filed 2023-11-08 |
| 2022-09-30 | $5.30B 10-Q · filed 2022-10-25 |
| 2022-06-30 | $6.55B 10-Q · filed 2022-07-20 |
| 2022-03-31 | $7.20B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $8.00B 10-Q · filed 2022-10-25 |
| 2021-09-30 | $8.05B 10-Q · filed 2021-10-20 |
| 2021-06-30 | $8.14B 10-Q · filed 2021-07-22 |
| 2021-03-31 | $7.86B 10-Q · filed 2021-04-22 |
| 2020-12-31 | $8.52B 10-Q · filed 2021-10-20 |
| 2020-09-30 | $8.34B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $8.26B 10-Q · filed 2020-07-22 |
| 2020-03-31 | $6.68B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $6.55B 10-Q · filed 2020-10-21 |
| 2019-09-30 | $6.49B 10-Q · filed 2019-10-22 |
| 2019-06-30 | $6.36B 10-Q · filed 2019-07-24 |
| 2019-03-31 | $6.16B 10-Q · filed 2019-04-24 |
| 2018-12-31 | $6.04B 10-Q · filed 2019-10-22 |
| 2018-09-30 | $6.11B 10-Q · filed 2018-10-23 |
| 2018-06-30 | $6.10B 10-Q · filed 2018-07-24 |
| 2018-03-31 | $6.19B 10-Q · filed 2018-04-24 |
| 2017-12-31 | $6.48B 10-K · filed 2019-02-06 |
| 2017-09-30 | $7.05B 10-Q · filed 2017-10-24 |
| 2017-06-30 | $7.01B 10-Q · filed 2017-07-25 |
| 2017-03-31 | $6.85B 10-Q · filed 2017-04-25 |
| 2016-12-31 | $6.81B 10-K · filed 2018-02-01 |
| 2016-09-30 | $7.21B 10-Q · filed 2016-10-26 |
| 2016-06-30 | $7.11B 10-Q · filed 2016-07-21 |
| 2016-03-31 | $7.05B 10-Q · filed 2016-04-21 |
| 2015-12-31 | $6.65B 10-K · filed 2017-02-02 |
| 2015-09-30 | $6.68B 10-Q · filed 2015-10-21 |
| 2015-06-30 | $631.50M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $646.80M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $647.20M 10-K · filed 2016-02-03 |
| 2014-09-30 | $650.90M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $659.70M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $665.10M 10-Q · filed 2014-04-23 |
| 2013-12-31 | $665.40M 10-K · filed 2015-02-04 |
| 2013-09-30 | $666.30M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $670.20M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $889.40M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $1.16B 10-K · filed 2014-02-06 |
| 2012-09-30 | $1.14B 10-Q · filed 2012-10-25 |
| 2012-06-30 | $1.15B 10-Q · filed 2012-07-24 |
| 2012-03-31 | $1.16B 10-Q · filed 2012-05-01 |
| 2011-12-31 | $1.16B 10-K · filed 2013-02-05 |
| 2011-09-30 | $1.17B 10-Q · filed 2011-10-28 |
| 2011-06-30 | $1.55B 10-Q · filed 2011-07-26 |
| 2011-03-31 | $1.14B 10-Q · filed 2011-04-21 |
| 2010-12-31 | $1.14B 10-K · filed 2012-02-03 |
| 2009-12-31 | $1.11B 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |